Jun
16
2026
Many people prescribed GLP-1 drugs for type 2 diabetes (such as Victoza, Ozempic, or tirzepatide) stop taking them, but a surprising number later return to treatment. Researchers found that newer medications appear to keep patients on therapy longer, while side effects remain a major reason for discontinuation.
Read More
Science Daily •
Diabetes for Doctors •
